Tony Ting – VJRegenMed

Addressing issues associated with bringing iSPC-derived MSCs to the clinic

Simon Ng — Thu, 03 Feb 2022 12:25:13 +0000

Tony Ting, PhD, Bone Therapeutics SA, Gosselies, Belgium, discusses challenges associated with developing cell therapies for clinical use. Chemistry, Manufacturing and Controls (CMC) remains a major barrier for many manufacturers, which lead to the creation of genetically engineered induced pluripotent stem cell-(iPSC)-derived mesenchymal stem cells (MSCs). Dr Ting additionally highlights how genetically engineered therapies can overcome regulatory issues relating to potency assays. This interview took place at Advanced Therapies Week 2022.

Enhancing the therapeutic capacity of MSCs

Simon Ng — Mon, 31 Jan 2022 17:59:08 +0000

Despite numerous clinical trials featuring mesenchymal stem cell (MSC)-based therapies, only a select few have reached clinical approval. Tony Ting, PhD, Bone Therapeutics SA, Gosselies, Belgium, describes strategies to professionalize MSCs. Expansion culture and differentiation of MSCs to promote bone healing in the ALLOB platform will hopefully unleash the full potential of MSCs. Dr Ting additionally comments on genetic manipulation of induced pluripotent stem cells (iPSCs) to professionalize MSCs, where iSPC-derived MSCs will lead to therapies with a consistent quality. This interview took place at Advanced Therapies Week 2022.

Evaluating the development of iSPC-derived MSCs

Simon Ng — Mon, 31 Jan 2022 17:59:05 +0000

Tony Ting, PhD, Bone Therapeutics SA, Gosselies, Belgium, provides an overview of the collaboration between Bone Therapeutics and Implant Therapeutics to research the differentiation of induced pluripotent stem cells (iPSCs) into mesenchymal stem cells (MSCs), as well as develop genetically engineered iPSC-derived MSCs. This interview took place at Advanced Therapies Week 2022.